10:25 am - March 26, 2026
The Accel Prosus India deep tech program has its first cohort, and the six companies it selected tell you more about the investment thesis than any press release language could. Cancer detection via dog breath analysis. Reusable orbital launch vehicles. Brain-computer interfaces. Optical satellite communications. This is not a typical seed round announcement from Sand Hill Road, and that appears to be the point.
Accel’s India team and Prosus Ventures jointly selected the six startups from a pool of more than 2,000 applications. The program was announced last October with an explicit mandate: back founders outside the industry’s usual playbook. That is a familiar pitch from deep tech funds. The deal structure behind it is less familiar.
Each check runs between $500,000 and $2 million. Both firms co-invest, with Prosus matching Accel dollar for dollar. Then comes the wrinkle: a portion of the capital is deferred, meaning founders give up equity at a later stage rather than at the moment of investment. The firms describe this as founder-friendly. Read it another way and it is also investor-friendly, delaying valuation negotiations until a startup has more data to support a number. For companies with long development cycles and no near-term revenue, that structure removes one of the hardest conversations in early-stage investing.
The Accel Prosus India Deep Tech Cohort: Six Companies, Six Long Bets
The roster spans hardware, biotech, and aerospace. Mumbai-based Praan is building air purification and sensing systems for indoor environments. It has prior backing from Avaana Capital, Social Impact Capital, and Aera VC. Bengaluru-based QOSMIC is working on optical communication systems to move data between satellites and Earth faster, with lower latency. Ethereal Exploration Guild, trading as EtherealX, is building reusable orbital launch vehicles. The company closed a $20.5 million Series A at an $80.5 million valuation, led by TDK Ventures and BIG Capital.
Then there is Dognosis. The company’s product, BreatheEasy, has patients breathe into a mask; the sample is then analyzed in a lab to detect cancer-linked markers using a combination of dogs’ olfactory sensitivity, robotics, and artificial intelligence. Multi-cancer early detection is a category drawing serious capital globally. Dognosis is attacking it from an angle that most investors would not have funded three years ago.
Ferra is building home-based strength training equipment that auto-adjusts resistance to match user performance, targeting the aging population’s mobility needs. The sixth company is in stealth, developing brain-computer interfaces.
Six different sectors. One common thread: none of these companies will produce meaningful revenue in the next 12 to 18 months.
The Accel Prosus India Deep Tech Investment Structure and What It Signals
The deferred equity model is not new. Convertible instruments and SAFEs have been a fixture of early-stage investing for over a decade. What makes this program worth watching is the institutional commitment behind it. Accel is one of the most active venture firms in India. Prosus has a balance sheet built on decades of returns from global tech investments. When two firms of that size build a dedicated structure for pre-revenue deep tech, it tells you something about where they think the next decade of Indian startup value creation is going.
India’s deep tech ecosystem has historically been underfunded relative to its software and consumer internet sectors. Regulatory barriers, long commercialization timelines, and thin domestic defense and aerospace procurement pipelines made the category difficult for generalist funds to underwrite. That calculus is shifting. Government programs supporting domestic space and defense technology, combined with growing global demand for supply chain diversification away from China, have opened market access that did not exist five years ago.
The Accel Prosus India deep tech cohort is a small bet on a large structural shift. Checks of $500,000 to $2 million do not build orbital launch vehicles or cancer diagnostic platforms to commercial scale. They buy time and optionality. The real question is what the follow-on funding looks like, and whether these firms have the conviction to lead Series A rounds in categories where most of their peers still won’t go.
The Accel Prosus India deep tech program says it selected startups that need time to make breakthroughs, not just capital. True enough. But in venture, time and capital are the same thing. The deferred equity structure buys founders a window. What they build in it determines whether the next check comes from the same table or somewhere else entirely.
The next cohort application cycle has not been announced. Watch the portfolio first.
